Identification of adipokine clusters related to parameters of fat mass, insulin sensitivity and inflammation

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Flehmig, Gesine ^a   Scholz, Markus ^a   Klöting, Nora ^a   Fasshauer, Mathias ^a   Tönjes, Anke ^a   Stumvoll, Michael ^a   Youn, Byung Soo ^b,c,d   Blüher, Matthias ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b Korea University   (South Korea)

^c University of Ulsan   (South Korea)

^d AdipoGen College of Life Science and Biotechnology Korea University ^*  (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; CHEMERIN; CLUSTERIN; CYTOKINE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; GLUTATHIONE PEROXIDASE 3; GLYPICAN; GLYPICAN 4; HEMOGLOBIN A1C; INSULIN; LEPTIN; METFORMIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OSTEOGENIC PROTEIN 1; PROGRANULIN; PROTEIN ANGPTL3; PROTEIN ANGPTL6; PROTEIN CTRP3; PROTEIN CTRP5; PROTEIN DLK1; PROTEIN DLL1; PROTEIN OMENTIN; RESISTIN; RETINOL BINDING PROTEIN 4; SECRETED FRIZZLED RELATED PROTEIN 5; SULFONYLUREA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASPIN; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; BODY WEIGHT; CAUCASIAN; CLUSTER ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC VALUE; FAT MASS; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; INFLAMMATION; INSULIN SENSITIVITY; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; VERY ELDERLY; BLOOD; INSULIN RESISTANCE; MIDDLE AGED;

ADIPOKINES; ADULT; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERGLYCEMIA; INFLAMMATION; INSULIN RESISTANCE; LIPID METABOLISM; MALE; MIDDLE AGED; OBESITY;

EID: 84903388618     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0099785     Document Type: Article

References (66)

1. Meisinger C, Strassburger K, Heier M, Thorand B, Baumeister SE et al. (2010) Prevalence of undiagnosed diabetes and impaired glucose regulation in 35-59-year-old individuals in Southern Germany: the KORA F4 Study. Diabet Med 27: 360-362.
2. DECODE Study Group (2003) Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care 26: 61-69.
3. Tönjes A, Fasshauer M, Kratzsch J, Stumvoll M, Blüher M et al. (2010) Adipokine Pattern in Subjects with Impaired Fasting Glucose and Impaired Glucose Tolerance in Comparison to Normal Glucose Tolerance and Diabetes. PLoS ONE 5: e13911.
4. Bastard J, Maachi M, Lagathu C, Kim MJ, Caron M et al. (2006) Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 17: 4-12.
5. Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N et al. (1997) Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest 100: 1166-1173.
6. Blüher M (2009) Adipose Tissue Dysfunction in Obesity. Exp Clin Endocrinol Diabetes 117: 241-250.
7. van Gaal LF, Mertens IL, de Block CE (2006) Mechanisms linking obesity with cardiovascular disease. Nature 444: 875-880. (Pubitemid 46028447)
8. Klöting N, Fasshauer M, Dietrich A, Kovacs P, Schön MR et al. (2010) Insulin-sensitive obesity. Am J Physiol Endocrinol Metab 299: E506-15.
9. Lehr S, Hartwig S, Sell H (2012) Adipokines: a treasure trove for the discovery of biomarkers for metabolic disorders. Proteomics Clin Appl 6: 91-101.
10. Suzuki R, Shimodaira H (2006) Pvclust: an R package for assessing the uncertainty in hierarchical clustering. Bioinformatics 22: 1540-1542. (Pubitemid 43985330)
11. Ahima RS, Flier JS (2000) Leptin. Annu Rev Physiol 62: 413-437. (Pubitemid 30618269)
12. Blüher M (2013) Adipose tissue dysfunction contributes to obesity related metabolic diseases. Best Pract Res Clin Endocrinol Metab 27: 163-177.
13. Park H, Green MH, Shaffer ML (2012) Association between serum retinol-binding protein 4 concentrations and clinical indices in subjects with type 2 diabetes: a meta-analysis. J Hum Nutr Diet 25: 300-310.
14. Klöting N, Graham TE, Berndt J, Kralisch S, Kovacs P et al. (2007) Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass. Cell Metab 6: 79-87. (Pubitemid 46995778)
15. Graham TE, Yang Q, Blüher M, Hammarstedt A, Ciaraldi TP et al. (2006) Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 354: 2552-2563. (Pubitemid 43882351)
16. Stefan N, Hennige AM, Staiger H, Machann J, Schick F et al. (2007) High circulating retinol-binding protein 4 is associated with elevated liver fat but not with total, subcutaneous, visceral, or intramyocellular fat in humans. Diabetes Care 30: 1173-1178. (Pubitemid 46684644)
17. Janke J, Engeli S, Boschmann M, Adams F, Bohnke J et al. (2006) Retinol-binding protein 4 in human obesity. Diabetes 55: 2805-2810. (Pubitemid 44923680)
18. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y et al. (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86: 1930-1935. (Pubitemid 32472900)
19. Turer AT, Scherer PE (2012) Adiponectin: mechanistic insights and clinical implications. Diabetologia 55: 2319-2326.
20. O'Connell J, Lynch L, Hogan A, Cawood TJ, O'Shea D (2011) Preadipocyte factor-1 is associated with metabolic profile in severe obesity. J Clin Endocrinol Metab 96: E680-E684.
21. Hu W, Li L, Yang M, Luo X, Ran W et al. (2013) Circulating Sfrp5 is a signature of obesity-related metabolic disorders and is regulated by glucose and liraglutide in humans. J Clin Endocrinol Metab 98: 290-298.
22. Youn B, Klöting N, Kratzsch J, Lee N, Park JW et al. (2007) Serum Vaspin Concentrations in Human Obesity and Type 2 Diabetes. Diabetes 57: 372-377.
23. Ussar S, Bezy O, Blüher M, Kahn CR (2012) Glypican-4 enhances insulin signaling via interaction with the insulin receptor and serves as a novel adipokine. Diabetes 61: 2289-2298.
24. Yoo HJ, Hwang SY, Hong HC, Choi HY, Yang SJ et al. (2013) Implication of Progranulin and C1q/TNF-Related Protein-3 (CTRP3) on Inflammation and Atherosclerosis in Subjects with or without Metabolic Syndrome. PLoS ONE 8: e55744.
25. de Souza Batista CM, Yang R, Lee M, Glynn NM, Yu D et al. (2007) Omentin Plasma Levels and Gene Expression Are Decreased in Obesity. Diabetes 56: 1655-1661. (Pubitemid 46842600)
26. Orlik B, Madej P, Owczarek A, Skalba P, Chudek J et al. (2013) Plasma omentin and adiponectin levels as markers of adipose tissue dysfunction in normal weight and obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf): DOI:10.1111/cen.12381.
27. Moreno-Navarrete JM, Catalan V, Ortega F, Gomez-Ambrosi J, Ricart W et al. (2010) Circulating omentin concentration increases after weight loss. Nutr Metab (Lond) 7: 27.
28. Ye R, Scherer PE (2013) Adiponectin, driver or passenger on the road to insulin sensitivity. Mol Metab 2: 133-141.
29. Blüher M, Rudich A, Klöting N, Golan R, Henkin Y et al. (2012) Two Patterns of Adipokine and Other Biomarker Dynamics in a Long-Term Weight Loss Intervention. Diabetes Care 35: 342-349.
30. Klöting N, Berndt J, Kralisch S, Kovacs P, Fasshauer M et al. (2006) Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun 339: 430-436. (Pubitemid 41697566)
31. Chakaroun R, Raschpichler M, Klöting N, Oberbach A, Flehmig G et al. (2012) Effects of weight loss and exercise on chemerin serum concentrations and adipose tissue expression in human obesity. Metabolism 61: 706-714.
32. Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J et al. (2007) Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 148: 4687-4694. (Pubitemid 47481514)
33. Hoofnagle AN, Wu M, Gosmanova AK, Becker JO, Wijsman EM et al. (2010) Low clusterin levels in high-density lipoprotein associate with insulin resistance, obesity, and dyslipoproteinemia. Arterioscler Thromb Vasc Biol 30: 2528-2534.
34. Berndt J, Klöting N, Kralisch S, Kovacs P, Fasshauer M et al. (2005) Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 54: 2911-2916. (Pubitemid 41401086)
35. Azuma K, Katsukawa F, Oguchi S, Murata M, Yamazaki H et al. (2003) Correlation between serum resistin level and adiposity in obese individuals. Obes Res 11: 997-1001. (Pubitemid 41137512)
36. Hotamisligil GS (2006) Inflammation and metabolic disorders. Nature 444: 860-867.
37. Dallmeier D, Larson MG, Vasan RS, Keaney JF Jr, Fontes JD et al. (2012) Metabolic syndrome and inflammatory biomarkers: a community-based crosssectional study at the Framingham Heart Study. Diabetol Metab Syndr 4: 28.
38. Karelis AD, Messier V, Brochu M, Rabasa-Lhoret R (2008) Metabolically healthy but obese women: effect of an energy-restricted diet. Diabetologia 51: 1752-1754.
39. van Vliet-Ostaptchouk JV, Nuotio M, Slagter SN, Doiron D, Fischer K et al. (2014) The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endocr Disord 14: 9.
40. Mather KJ, Funahashi T, Matsuzawa Y, Edelstein S, Bray GA et al. (2008) Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program. Diabetes 57: 980-986.
41. Tan BK, Heutling D, Chen J, Farhatullah S, Adya R et al. (2008) Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance. Diabetes 57: 1501-1507.
42. Kadoglou NPE, Gkontopoulos A, Kapelouzou A, Fotiadis G, Theofilogiannakos EK et al. (2011) Serum levels of vaspin and visfatin in patients with coronary artery disease-Kozani study. Clin Chim Acta 412: 48-52.
43. Tan BK, Adya R, Farhatullah S, Chen J, Lehnert H et al. (2010) Metformin treatment may increase omentin-1 levels in women with polycystic ovary syndrome. Diabetes 59: 3023-3031.
44. Laudes M, Oberhauser F, Schulte DM, Freude S, Bilkovski R et al. (2010) Visfatin/PBEF/Nampt and Resistin Expressions in Circulating Blood Monocytes are Differentially Related to Obesity and Type 2 Diabetes in Humans. Horm Metab Res 42: 268-273.
45. Hida K, Wada J, Eguchi J, Zhang H, Baba M et al. (2005) Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A 102: 10610-10615. (Pubitemid 41061602)
46. Lee JA, Park HS, Song YS, Jang YJ, Kim J et al. (2011) Relationship between vaspin gene expression and abdominal fat distribution of Korean women. Endocr J 58: 639-646.
47. Tseng Y, Kokkotou E, Schulz TJ, Huang TL, Winnay JN et al. (2008) New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure. Nature 454: 1000-1004.
48. Fruhbeck G, Becerril S, Sainz N, Garrastachu P, Garcia-Velloso MJ (2009) BAT: a new target for human obesity. Trends Pharmacol Sci 30: 387-396.
49. Zeng J, Jiang Y, Xiang S, Chen B (2011) Serum bone morphogenetic protein 7, insulin resistance, and insulin secretion in non-diabetic individuals. Diabetes Res Clin Pract 93: e21-4.
50. Zhang H, Schulz TJ, Espinoza DO, Huang TL, Emanuelli B et al. (2010) Cross talk between insulin and bone morphogenetic protein signaling systems in brown adipogenesis. Mol Cell Biol 30: 4224-4233.
51. Kettaneh A, Heude B, Oppert J, Scherer P, Meyre D et al. (2006) Serum adiponectin is related to plasma high-density lipoprotein cholesterol but not to plasma insulin-concentration in healthy children: the FLVS II study. Metabolism 55: 1171-1176.
52. Vangipurapu J, Stancakova A, Kuulasmaa T, Paananen J, Kuusisto J et al. (2011) A novel surrogate index for hepatic insulin resistance. Diabetologia 54: 540-543.
53. Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S et al. (2010) Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 33: 920-922.
54. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R (2002) Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 290: 1084-1089. (Pubitemid 34687474)
55. Kadoglou NPE, Kapelouzou A, Tsanikidis H, Vitta I, Liapis CD et al. (2011) Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naive patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 119: 63-68.
56. Montague CT, O'Rahilly S (2000) The perils of portliness: causes and consequences of visceral adiposity. Diabetes 49: 883-888. (Pubitemid 30349408)
57. Kuk JL, Katzmarzyk PT, Nichaman MZ, Church TS, Blair SN et al. (2006) Visceral fat is an independent predictor of all-cause mortality in men. Obesity (Silver Spring) 14: 336-341. (Pubitemid 46214766)
58. Rasouli N, Molavi B, Elbein SC, Kern PA (2007) Ectopic fat accumulation and metabolic syndrome. Diabetes Obes Metab 9: 1-10. (Pubitemid 44921036)
59. Tan BK, Chen J, Hu J, Amar O, Mattu HS et al. (2013) Metformin Increases the Novel Adipokine Cartonectin/CTRP3 in Women With Polycystic Ovary Syndrome. J Clin Endocrinol Metab 98: E1891-900.
60. Tan BK, Chen J, Farhatullah S, Adya R, Kaur J et al. (2009) Insulin and metformin regulate circulating and adipose tissue chemerin. Diabetes 58: 1971-1977.
61. Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC et al. (2007) Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem 282: 28175-28188. (Pubitemid 47529521)
62. Youn B, Bang S, Klöting N, Park JW, Lee N et al. (2009) Serum progranulin concentrations may be associated with macrophage infiltration into omental adipose tissue. Diabetes 58: 627-636.
63. Matsubara T, Mita A, Minami K, Hosooka T, Kitazawa S et al. (2012) PGRN is a key adipokine mediating high fat diet-induced insulin resistance and obesity through IL-6 in adipose tissue. Cell Metab 15: 38-50.
64. Wittamer V, Franssen J, Vulcano M, Mirjolet J, Le Poul E et al. (2003) Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med 198: 977-985. (Pubitemid 37248614)
65. Kengne AP, Beulens JW, Peelen LM, Moons KG, van der Schouw YT et al. (2014) Non-invasive risk scores for prediction of type 2 diabetes (EPIC-InterAct): a validation of existing models. Lancet Diabetes Endocrinol 2: 19-29.
66. Spranger J, Kroke A, Mohlig M, Bergmann MM, Ristow M et al. (2003) Adiponectin and protection against type 2 diabetes mellitus. Lancet 36153): 226-228.